Henry Koon

6.1k total citations
59 papers, 2.9k citations indexed

About

Henry Koon is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Henry Koon has authored 59 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 22 papers in Molecular Biology and 22 papers in Immunology. Recurrent topics in Henry Koon's work include CAR-T cell therapy research (16 papers), Melanoma and MAPK Pathways (12 papers) and Immunotherapy and Immune Responses (12 papers). Henry Koon is often cited by papers focused on CAR-T cell therapy research (16 papers), Melanoma and MAPK Pathways (12 papers) and Immunotherapy and Immune Responses (12 papers). Henry Koon collaborates with scholars based in United States, Netherlands and Italy. Henry Koon's co-authors include Christopher L. Carpenter, Francisca Vázquez, Hongbing Zhang, Gregor Cicchetti, Hiroaki Onda, David J. Kwiatkowski, Michael B. Atkins, Bruce J. Dezube, Philip W. Tucker and Alison H. Banham and has published in prestigious journals such as Journal of Clinical Investigation, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Henry Koon

56 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Henry Koon United States	25	1.4k	1.3k	910	447	282	59	2.9k
Shenghui Duan United States	19	1.3k 0.9×	704 0.5×	1.2k 1.4×	448 1.0×	201 0.7×	30	3.4k
Els M.E. Verdegaal Netherlands	24	1.1k 0.8×	1.6k 1.2×	1.6k 1.7×	218 0.5×	213 0.8×	62	3.1k
Andreas Gast Germany	19	2.1k 1.6×	957 0.7×	462 0.5×	401 0.9×	232 0.8×	28	3.3k
Ferenc A. Scheeren Netherlands	26	1.4k 1.0×	1.2k 0.9×	1.5k 1.7×	153 0.3×	249 0.9×	49	3.4k
Yoko Oei United States	12	1.4k 1.0×	1.1k 0.8×	1.9k 2.1×	332 0.7×	278 1.0×	17	3.6k
Riccardo Mezzadra United States	9	1.1k 0.8×	1.9k 1.5×	1.5k 1.7×	194 0.4×	415 1.5×	14	3.2k
Moitreyee Chatterjee‐Kishore United States	16	1.3k 0.9×	1.0k 0.8×	992 1.1×	141 0.3×	114 0.4×	20	2.5k
Carlos Bais United States	20	1.9k 1.4×	1.9k 1.4×	1.0k 1.1×	302 0.7×	318 1.1×	38	4.1k
Martina Seiffert Germany	32	1.2k 0.9×	592 0.4×	1.5k 1.7×	247 0.6×	120 0.4×	80	3.1k
Lyn Healy United Kingdom	27	1.3k 1.0×	714 0.5×	588 0.6×	200 0.4×	93 0.3×	59	2.7k

Countries citing papers authored by Henry Koon

Since Specialization

Citations

This map shows the geographic impact of Henry Koon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henry Koon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henry Koon more than expected).

Fields of papers citing papers by Henry Koon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henry Koon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henry Koon. The network helps show where Henry Koon may publish in the future.

Co-authorship network of co-authors of Henry Koon

This figure shows the co-authorship network connecting the top 25 collaborators of Henry Koon. A scholar is included among the top collaborators of Henry Koon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henry Koon. Henry Koon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bajorin, Dean F., J. Alfred Witjes, Jürgen E. Gschwend, et al.. (2021). First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC).. Journal of Clinical Oncology. 39(6_suppl). 391–391. 30 indexed citations

Khushalani, Nikhil I., Adi Diab, Paolo A. Ascierto, et al.. (2020). Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. Future Oncology. 16(28). 2165–2175. 17 indexed citations

Eads, Jennifer R., Smitha Krishnamurthi, Joel Saltzman, et al.. (2020). Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors. Investigational New Drugs. 39(1). 142–151. 10 indexed citations

Rambhia, Pooja H., Jeffrey F. Scott, Ashley Feneran, et al.. (2019). Immune checkpoint inhibitor-induced sarcoidosis-like granulomas. International Journal of Clinical Oncology. 24(10). 1171–1181. 35 indexed citations

Wat, Margaret, et al.. (2018). 169 Efficacy and tolerability of pembrolizumab in an elderly patient and unusual presentation of advanced stage metastatic merkel cell carcinoma. Journal of Investigative Dermatology. 138(5). S29–S29.

Amin, Asim, David H. Lawson, April K.S. Salama, et al.. (2016). Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. Journal for ImmunoTherapy of Cancer. 4(1). 44–44. 51 indexed citations

Koon, Henry, et al.. (2014). Current Systemic Therapies for Melanoma. Dermatologic Surgery. 40(9). 948–963. 18 indexed citations

Faulhaber, Peter, et al.. (2014). Delayed response in ipilimumab therapy. The Journal of Community and Supportive Oncology. 12(3). 109–110. 1 indexed citations

Shamay, Meir, Nicholas J. Hand, M. Victor Lemas, et al.. (2012). CpG Methylation as a Tool to Characterize Cell-Free Kaposi Sarcoma Herpesvirus DNA. The Journal of Infectious Diseases. 205(7). 1095–1099. 14 indexed citations

10.

Fan, Weiwen, Zhe Tang, Lihong Yin, et al.. (2011). MET-Independent Lung Cancer Cells Evading EGFR Kinase Inhibitors Are Therapeutically Susceptible to BH3 Mimetic Agents. Cancer Research. 71(13). 4494–4505. 59 indexed citations

11.

Koon, Henry, Barbara Fingleton, Jeannette Y. Lee, et al.. (2010). Phase II AIDS Malignancy Consortium Trial of Topical Halofuginone in AIDS-Related Kaposi Sarcoma. JAIDS Journal of Acquired Immune Deficiency Syndromes. 56(1). 64–68. 47 indexed citations

12.

Cho, Daniel C., Igor Puzanov, Meredith M. Regan, et al.. (2009). Retrospective Analysis of the Safety and Efficacy of Interleukin-2 After Prior VEGF-targeted Therapy in Patients With Advanced Renal Cell Carcinoma. Journal of Immunotherapy. 32(2). 181–185. 35 indexed citations

13.

Koon, Henry & Michael B. Atkins. (2006). Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance. Expert Review of Anticancer Therapy. 7(1). 79–88. 30 indexed citations

14.

Sullivan, Ryan J., Bruce J. Dezube, & Henry Koon. (2006). Signal transduction targets in Kaposi's sarcoma. Current Opinion in Oncology. 18(5). 456–462. 19 indexed citations

15.

Dezube, Bruce J., Ryan J. Sullivan, & Henry Koon. (2006). Emerging targets and novel strategies in the treatment of AIDS‐related Kaposi's sarcoma: Bidirectional translational science. Journal of Cellular Physiology. 209(3). 659–662. 21 indexed citations

16.

Raggo, Camilo, Rebecca Ruhl, Shane C. McAllister, et al.. (2005). Novel Cellular Genes Essential for Transformation of Endothelial Cells by Kaposi's Sarcoma–Associated Herpesvirus. Cancer Research. 65(12). 5084–5095. 99 indexed citations

17.

Koon, Henry, David Hägg, Kathryn L. Butler, et al.. (2005). Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing. Leukemia Research. 30(2). 190–203. 23 indexed citations

18.

Saito, Kan, Kimberley F. Tolias, Abdelhafid Saci, et al.. (2003). BTK Regulates PtdIns-4,5-P2 Synthesis. Immunity. 19(5). 669–677. 173 indexed citations

19.

Zhang, Hongbing, Gregor Cicchetti, Hiroaki Onda, et al.. (2003). Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. Journal of Clinical Investigation. 112(8). 1223–1233. 432 indexed citations

20.

Koon, Henry & Richard P. Junghans. (2000). Anti-CD30 antibody–based therapy. Current Opinion in Oncology. 12(6). 588–593. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact